NCT05177276View on ClinicalTrials.gov

Selinexor Combination Ph 1 Study

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Solid Tumor Malignancy
Interventions
DRUG

Selinexor

DRUG

Irinotecan

Trial Locations (1)

07601

John Theurer Cancer Center at HackensackUMC, Hackensack

Sponsors
All Listed Sponsors
collaborator

Hackensack Meridian Health

OTHER

collaborator

Karyopharm Therapeutics Inc

INDUSTRY

lead

Martin Gutierrez

OTHER

NCT05177276 - Selinexor Combination Ph 1 Study | Biotech Hunter | Biotech Hunter